Fortive Corp (FTV) · Oct 28, 2026 · Earnings

Fortive earnings beat as EPS guidance rises, healthcare slips

Beat — Adj. EPS $0.77 vs ~$0.70 consensus; FY guide raised to $3.10-$3.14

Fortive earnings beat Q3 expectations and raised full-year adjusted EPS guidance, though Advanced Healthcare Solutions posted weaker profit and margins.

Fortive is a technology-solutions company now focused on Intelligent Operating Solutions and Advanced Healthcare Solutions, executing its “Fortive Accelerated” strategy around faster organic growth, disciplined capital allocation, and recurring customer value.

MetricQ3 2026Q3 2025Comparison
Revenue$1,107.5M$1,027.1M+7.8% reported; +7.2% core
Adjusted diluted EPS$0.77$0.68+13.2%; versus ~$0.70 consensus
Adjusted EBITDA$338.8M$309.4M+9.5%
Adjusted EBITDA margin30.6%30.1%+50 bps
Free cash flow$283.8M$266.1M+6.7%
FY2026 adjusted EPS guidance$3.10-$3.14$2.95-$3.05 prior rangeRaised

The quarter cleared the market’s bar by a meaningful margin. Adjusted EPS of $0.77 exceeded the roughly $0.70 published consensus, while revenue of $1.108 billion also topped the approximately $1.07 billion expectation. The result was driven by broad operating leverage and a 7.2% core-revenue increase, not just accounting noise. “We delivered over 7% core growth, approximately 10% adjusted EBITDA growth, and 13% adjusted EPS growth, representing our fifth consecutive quarter of double-digit adjusted EPS growth.” 〔0〕

Intelligent Operating Solutions is carrying the acceleration story. IOS revenue grew 9.1% organically, while adjusted EBITDA rose 13.6% and its adjusted EBITDA margin expanded 120 basis points to 35.8%. That is the cleanest evidence in the filing that Fortive’s commercial and innovation investments are translating into faster growth with incremental profitability. (Segment results — Intelligent Operating Solutions)

Advanced Healthcare Solutions remains the material weak spot. AHS delivered only 3.1% core growth, and adjusted EBITDA fell 4.8% as its margin contracted 230 basis points to 25.8%. The filing does not identify a single cause that fully explains the deterioration, so the segment’s weaker profitability is a genuine execution or mix issue rather than something that can be dismissed from the consolidated beat. (Segment results — Advanced Healthcare Solutions)

The raised outlook makes the beat more consequential than a routine quarterly upside. Fortive lifted full-year adjusted EPS guidance to $3.10-$3.14 from the prior $2.95-$3.05 range, putting the midpoint above the roughly $3.00 published full-year expectation. “We are raising our full-year adjusted EPS guidance to $3.10 to $3.14, reflecting our strong year-to-date performance and our confidence in the trajectory of the business.”

Cash generation supports the quality of the result, but leverage deserves context. Year-to-date operating cash flow from continuing operations reached $832.4 million versus $691.5 million a year earlier, and trailing-twelve-month free cash flow reached $1.062 billion versus $921.9 million. At the same time, long-term debt rose to $3.514 billion from $2.307 billion at year-end, while the company repurchased $1.000 billion of shares through nine months. (Cash Flow statement; Balance Sheet)

Bottom line: This is a genuine upside quarter: Fortive beat earnings and revenue expectations, then raised its full-year EPS range above the prior outlook and market benchmark. The main qualification is that the improvement is concentrated in IOS while healthcare profitability is moving the other way, making AHS the key unresolved part of the story.

Original filing on SEC EDGAR

More Fortive Corp news

Fortive earnings beat as EPS guidance rises, healthcare slips | FTV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.